How AI Is Changing Drug Discovery at Isomorphic Labs

What happened: Max Jaderberg, President of Isomorphic Labs, discussed at Bloomberg Tech in London how AI is accelerating scientific discovery and opening new approaches to drug development. Isomorphic Labs began in 2021 as a spin out of Alphabet's Google DeepMind. Why it matters: Jaderberg said the company uses its AI drug design engine to make medicines for patients rather than selling access to the models, tokens, or API access. He cited commercial partnerships with Eli Lilly, Novartis, and Johnson and Johnson. Market: -0.2% today ($277.52), -11.9% YTD, 0.2x vol — as of 15:18 UTC

Max Jaderberg, President of Isomorphic Labs, discussed at Bloomberg Tech in London how AI is accelerating scientific discovery and opening new approaches to drug development. Isomorphic Labs began in 2021 as a spin out of Alphabet's Google DeepMind.

Jaderberg said the company uses its AI drug design engine to make medicines for patients rather than selling access to the models, tokens, or API access. He cited commercial partnerships with Eli Lilly, Novartis, and Johnson and Johnson. Market: -0.2% today ($277.52), -11.9% YTD, 0.2x vol — as of 15:18 UTC